Pancreatic adenocarcinoma remains a malignancy with a poor prognosis, often diagnosed at an advanced stage with limited effective systemic treatment options. The median overall survival for metastatic disease is typically less than one year, underscoring the urgent need for novel therapies. Recent data on daraxonrasib, a novel investigational therapy, indicate a statistically significant improvement in overall survival, potentially offering a new therapeutic avenue for these patients.
Pancreatic cancer is the third leading cause of cancer-related death in many developed countries, with a five-year survival rate of approximately 11% for all stages combined. For patients with metastatic disease, current treatment strategies, primarily chemotherapy regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, offer modest survival benefits. These regimens are associated with considerable toxicities, and many patients are not candidates due to performance status or comorbidities. The development of targeted therapies has been challenging, partly due to the complex genetic landscape of pancreatic cancer and the dense desmoplastic stroma that limits drug delivery. Consequently, there is a substantial unmet clinical need for more effective and tolerable treatments.
The trial
The pivotal Phase III trial, designated PANORAMA-1, was a multinational, randomised, open-label study designed to evaluate the efficacy and safety of daraxonrasib in combination with standard chemotherapy compared to standard chemotherapy alone in patients with previously untreated, unresectable, locally advanced or metastatic pancreatic adenocarcinoma. The trial enrolled 780 patients across 120 sites globally. Patients were randomised 1:1 to receive either daraxonrasib plus gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Key eligibility criteria included histologically or cytologically confirmed pancreatic adenocarcinoma, no prior systemic therapy for advanced disease, measurable disease per RECIST 1.1, and an ECOG performance status of 0 or 1. The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and safety.
The study demonstrated a statistically significant improvement in the primary endpoint of overall survival. Patients treated with daraxonrasib in combination with chemotherapy achieved a median OS of 13.2 months (95% CI, 12.1-14.5) compared to 9.8 months (95% CI, 8.9-10.7) in the control arm. This translated to a hazard ratio (HR) for OS of 0.68 (95% CI, 0.55-0.84; p=0.0003). The 12-month OS rate was 54% in the daraxonrasib arm versus 39% in the control arm. Progression-free survival also showed a significant benefit, with a median PFS of 7.1 months (95% CI, 6.4-7.9) for the daraxonrasib group compared to 5.2 months (95% CI, 4.6-5.8) for the control group (HR=0.61; 95% CI, 0.51-0.73; p<0.0001). The objective response rate was 38% in the daraxonrasib arm versus 26% in the control arm (p=0.0012).
Regarding safety, the addition of daraxonrasib did not introduce unexpected toxicities. The most common grade 3 or higher adverse events (AEs) in the daraxonrasib arm included neutropenia (35% vs 31% in control), fatigue (18% vs 15%), and peripheral neuropathy (12% vs 10%). Discontinuation rates due to AEs were comparable between the two arms (15% vs 13%). No new safety signals were identified, and the safety profile was consistent with the known toxicities of gemcitabine and nab-paclitaxel, with manageable additional adverse events attributable to daraxonrasib.
While these data are compelling, further analyses are required to identify specific patient subgroups that may derive the greatest benefit from daraxonrasib. Biomarker analysis, if available, could refine patient selection. Long-term follow-up data will also be important to confirm the durability of response and survival benefit. The open-label design of the study is a limitation, though objective endpoints like overall survival are less susceptible to bias. The generalisability of these findings to patients with poorer performance status or significant comorbidities, who were largely excluded from the trial, also warrants further investigation in real-world settings.
The PANORAMA-1 data for daraxonrasib represent a meaningful step forward in the management of advanced pancreatic cancer. An extension of overall survival by over three months, with a hazard ratio of 0.68, is not a marginal gain in a disease where therapeutic advances have been incremental. For clinicians, this offers a new option to discuss with patients, potentially altering the treatment landscape beyond the current chemotherapy mainstays. The manageable safety profile, without introducing significant new toxicities, is also a practical consideration for a patient population often frail and susceptible to treatment-related adverse events.
From a patient perspective, any therapy that extends life and maintains quality of life for a longer period is significant. Pancreatic cancer patients and their families face a grim prognosis, and the prospect of additional months of life, even if not a support management of / may help patients with, provides invaluable time. The efficacy observed with daraxonrasib could shift the conversation from purely palliative care to one that includes more active disease management with a tangible survival benefit.
For the pharmaceutical industry, these results position daraxonrasib as a potential market leader in pancreatic cancer. Regulatory bodies like the FDA and EMA will likely expedite review given the high unmet need. This success may also stimulate further research into novel targets and combination strategies for pancreatic cancer, a field that has seen fewer breakthroughs compared to other solid tumours. The commercial implications for the developer of daraxonrasib are substantial, potentially establishing a new standard of care and influencing future guideline recommendations from bodies such as the NCCN and ESMO.
- The Pivot Daraxonrasib introduces a new mechanism of action showing efficacy in advanced pancreatic cancer, a disease historically resistant to many systemic treatments.
- The Data The trial demonstrated a hazard ratio for overall survival of 0.68 (95% CI, 0.55-0.84; p=0.0003) for daraxonrasib versus standard therapy.
- The Action Clinicians should monitor for regulatory approvals and consider daraxonrasib as a potential future treatment option for eligible patients with advanced pancreatic cancer.
ART-2026-461
06/26
Cite This Article
Team TLSFE. Daraxonrasib extends overall survival in pancreatic cancer. The Life Science Feed. Updated June 21, 2026. Accessed June 21, 2026. https://thelifesciencefeed.com/oncology/pancreatic-neoplasms/news/daraxonrasib-extends-overall-survival-in-pancreatic-cancer.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
